The Centre for Eye Research Australia Limited is an independent not-for-profit medical research institute focused on preventing vision loss and blindness through innovative eye research. Established in 1996 and incorporated as a company limited by guarantee, it conducts discovery science, clinical trials, epidemiological studies, and translational research on key conditions such as glaucoma, age-related macular degeneration, inherited retinal diseases, and diabetic retinopathy.
Based in East Melbourne, Victoria, Australia, CERA is co-located at the Royal Victorian Eye and Ear Hospital and affiliated with the University of Melbourne within the Department of Surgery, Melbourne Medical School. It operates Cerulea Clinical Trials as its dedicated not-for-profit clinical trials centre and maintains status as a World Health Organization Collaborating Centre for the Prevention of Blindness, the sole such centre in Australia. The institute ranks in the global top five for ophthalmology research.
CERA's work spans ophthalmic neuroscience, bionic eye development, retinal imaging biomarkers, neuroprotection, gene therapy spin-outs like Mirugen, and population health initiatives including national eye health surveys. It collaborates with over 100 international research organizations, industry partners, and government bodies to accelerate the development of new diagnostics, treatments, and prevention strategies. As a health promotion charity and deductible gift recipient, its structure supports philanthropic funding alongside competitive grants to drive real-world impact in vision science.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.
